# EDGAR Filing Document

**Accession Number:** 0001069899
**File Stem:** 0001104659-25-107913
**Filing Date:** 2025-11
**Character Count:** 9738
**Document Hash:** 3a4ca35e08a227196db048bbaed6e363
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107913.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001104659-25-107913

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251104

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BENDHEIM JACK
- **CENTRAL INDEX KEY:** 0001241560

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36410
- **FILM NUMBER:** 251459816

**MAIL ADDRESS:**
- **STREET 1:** C/O PHIBRO ANIMAL HEALTH CORP
- **STREET 2:** 300 FRANK W. BURR BLVD., STE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BFI Co., LLC
- **CENTRAL INDEX KEY:** 0001601607

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36410
- **FILM NUMBER:** 251459815

**BUSINESS ADDRESS:**
- **STREET 1:** 300 FRANK W. BURR BLVD., STE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666
- **BUSINESS PHONE:** 2013297300

**MAIL ADDRESS:**
- **STREET 1:** 300 FRANK W. BURR BLVD., STE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PHIBRO ANIMAL HEALTH CORP
- **CENTRAL INDEX KEY:** 0001069899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 131840497
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** GLENPOINTE CENTRE EAST, 3RD FLOOR
- **STREET 2:** 300 FRANK W. BURR BLVD., SUITE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666
- **BUSINESS PHONE:** 201-329-7300

**MAIL ADDRESS:**
- **STREET 1:** GLENPOINTE CENTRE EAST, 3RD FLOOR
- **STREET 2:** 300 FRANK W. BURR BLVD., SUITE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHILIPP BROTHERS CHEMICALS INC
- **DATE OF NAME CHANGE:** 19980908

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BENDHEIM JACK<br><sub>(Last) (First) (Middle)</sub><br>300 FRANK W. BURR BLVD., STE 21<br><sub>(Street)</sub><br>TEANECK, NJ 07666<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>PHIBRO ANIMAL HEALTH CORP [ PAHC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BFI Co., LLC<br><sub>(Last) (First) (Middle)</sub><br>300 FRANK W. BURR BLVD., STE 21<br><sub>(Street)</sub><br>TEANECK, NJ 07666<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>PHIBRO ANIMAL HEALTH CORP [ PAHC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2025-11-04 |  | C<sup>(1)</sup> |  | 25000 | A | $0 | 69440 | I | See<sup>(2)</sup> |
| Class A Common Stock | 2025-11-04 |  | S<sup>(3)</sup> |  | 2996 | D | 43.0061<sup>(4)</sup> | 66444 | I | See<sup>(2)</sup> |
| Class A Common Stock | 2025-11-04 |  | S<sup>(3)</sup> |  | 524 | D | 43.6205<sup>(5)</sup> | 65920 | I | See<sup>(2)</sup> |
| Class A Common Stock | 2025-11-05 |  | S<sup>(3)</sup> |  | 2548 | D | 40.9805<sup>(6)</sup> | 63372 | I | See<sup>(2)</sup> |
| Class A Common Stock | 2025-11-05 |  | S<sup>(3)</sup> |  | 972 | D | 41.8278<sup>(7)</sup> | 62400 | I | See<sup>(2)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 16840 | D<sup>(8)</sup> |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Class B Common Stock | $0 | 2025-11-04 |  | C |  |  | 25000 | <sup>(1)</sup> | <sup>(1)</sup> | Class A Common Stock | 25000 | $0 | 20061034 | I | See<sup>(2)</sup> |

---

### Footnotes:

(1) Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

(2) The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

(3) The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

(4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7.

(5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.555 to $43.705.

(6) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.535.

(7) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $42.14.

(8) The reported securities are directly held by Jack Bendheim.

**Signature:** /s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim  
**Date:** 2025-11-06

**Signature:** /s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC  
**Date:** 2025-11-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**